Biohaven Ltd. (BHVN)
12.92
-0.27
(-2.05%)
USD |
NYSE |
Sep 25, 12:48
Biohaven Enterprise Value : 2.021B for Sept. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 24, 2026 | 2.021B |
| September 23, 2026 | 2.093B |
| September 22, 2026 | 2.272B |
| September 21, 2026 | 2.177B |
| September 18, 2026 | 2.086B |
| September 17, 2026 | 2.127B |
| September 16, 2026 | 1.844B |
| September 15, 2026 | 1.893B |
| September 14, 2026 | 1.938B |
| September 11, 2026 | 1.948B |
| September 10, 2026 | 1.961B |
| September 09, 2026 | 2.294B |
| September 08, 2026 | 2.252B |
| September 04, 2026 | 2.399B |
| September 03, 2026 | 2.424B |
| September 02, 2026 | 2.399B |
| September 01, 2026 | 2.406B |
| August 31, 2026 | 2.335B |
| August 28, 2026 | 2.356B |
| August 27, 2026 | 2.463B |
| August 26, 2026 | 2.589B |
| August 25, 2026 | 2.201B |
| August 24, 2026 | 2.095B |
| August 21, 2026 | 2.121B |
| August 20, 2026 | 2.068B |
| Date | Value |
|---|---|
| August 19, 2026 | 2.164B |
| August 18, 2026 | 2.078B |
| August 17, 2026 | 2.213B |
| August 14, 2026 | 2.240B |
| August 13, 2026 | 2.272B |
| August 12, 2026 | 2.202B |
| August 11, 2026 | 2.217B |
| August 10, 2026 | 2.225B |
| August 07, 2026 | 2.243B |
| August 06, 2026 | 2.207B |
| August 05, 2026 | 2.087B |
| August 04, 2026 | 2.106B |
| August 03, 2026 | 2.048B |
| July 31, 2026 | 2.068B |
| July 30, 2026 | 2.116B |
| July 29, 2026 | 2.057B |
| July 28, 2026 | 2.109B |
| July 27, 2026 | 2.220B |
| July 24, 2026 | 2.192B |
| July 23, 2026 | 2.241B |
| July 22, 2026 | 2.257B |
| July 21, 2026 | 2.371B |
| July 20, 2026 | 2.273B |
| July 17, 2026 | 2.361B |
| July 16, 2026 | 2.169B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.228M |
| Brainstorm Cell Therapeutics, Inc. | 11.83M |
| Summit Therapeutics, Inc. | 12.32B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | 58.19M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -137.31M |
| Total Expenses (Quarterly) | 137.31M |
| EPS Diluted (Quarterly) | -0.9115 |
| Earnings Yield | -35.96% |
| Normalized Earnings Yield | -35.55 |